Drug and Therapeutics Bulletin 2000;38:15-16; doi:10.1136/dtb.2000.38215
Copyright © 2000 by the BMJ Publishing Group Ltd.
Rivastigmine for Alzheimer's disease
Relevant BNF section: 4.11
Rivastigmine (Exelon - Novartis) is the second cholinesterase inhibitor marketed for symptomatic treatment of mild to moderately severe Alzheimer's dementia, and follows donepezil (Aricept - Eisai; Pfizer). Previously, we have been "unconvinced of the value of donepezil in routine clinical practice".1,2 Rivastigmine has been promoted with the slogan "Beyond cognition: improving functional ability". Does rivastigmine offer useful benefits in Alzheimer's disease?
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Heller, T., Heller, L.
(2003). First among Equals?: Does drug treatment for dementia claim more than its fair share of resources?. Dementia
2: 7-19
[Abstract]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
